163 related articles for article (PubMed ID: 34028367)
1. Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.
Cardwell CR; McDowell RD; Hughes CM; Hicks B; Murchie P
Am J Gastroenterol; 2021 Aug; 116(8):1612-1619. PubMed ID: 34028367
[TBL] [Abstract][Full Text] [Related]
2. Ranitidine and Risk of Bladder and Kidney Cancer: A Population-Based Cohort Study.
Nørgaard M; Andersen IT; Heide-Jørgensen U; Erichsen R; Rees JR; Karagas MR; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):45-50. PubMed ID: 34649959
[TBL] [Abstract][Full Text] [Related]
3. Ranitidine Use and Risk of Upper Gastrointestinal Cancers.
Adami HO; Trolle Andersen I; Heide-Jørgensen U; Chang ET; Nørgaard M; Sørensen HT
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2302-2308. PubMed ID: 34620629
[TBL] [Abstract][Full Text] [Related]
4. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018.
Iwagami M; Kumazawa R; Miyamoto Y; Ito Y; Ishimaru M; Morita K; Hamada S; Tamiya N; Yasunaga H
Drug Saf; 2021 Mar; 44(3):361-371. PubMed ID: 33247391
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
6. The effect of medications associated with drug-induced pancreatitis on pancreatic cancer risk: A nested case-control study of routine Scottish data.
McDowell RD; Hughes CM; Murchie P; Cardwell CR
Cancer Epidemiol; 2021 Apr; 71(Pt A):101880. PubMed ID: 33422975
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
Liu P; McMenamin ÚC; Johnston BT; Murchie P; Iversen L; Lee AJ; Vissers PAJ; Cardwell CR
Br J Cancer; 2020 Jul; 123(2):307-315. PubMed ID: 32367073
[TBL] [Abstract][Full Text] [Related]
8. Histamine-2 receptor antagonists and gastric cancer.
Johnson AG; Jick SS; Perera DR; Jick H
Epidemiology; 1996 Jul; 7(4):434-6. PubMed ID: 8793372
[TBL] [Abstract][Full Text] [Related]
9. Ranitidine Use and Incident Cancer in a Multinational Cohort.
You SC; Seo SI; Falconer T; Yanover C; Duarte-Salles T; Seager S; Posada JD; Shah NH; Nguyen PA; Kim Y; Hsu JC; Van Zandt M; Hsu MH; Lee HL; Ko H; Shin WG; Pratt N; Park RW; Reich CG; Suchard MA; Hripcsak G; Park CH; Prieto-Alhambra D
JAMA Netw Open; 2023 Sep; 6(9):e2333495. PubMed ID: 37725377
[TBL] [Abstract][Full Text] [Related]
10. The role of 5α-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study.
Busby J; Karasneh R; Murchie P; McMenamin Ú; Gadalla SM; Camargo MC; Iversen L; Lee AJ; Spence AD; Cardwell CR
Pharmacoepidemiol Drug Saf; 2020 Jan; 29(1):48-56. PubMed ID: 31713940
[TBL] [Abstract][Full Text] [Related]
11. Use of proton pump inhibitors and risk of pancreatic cancer.
Hicks B; Friis S; Pottegård A
Pharmacoepidemiol Drug Saf; 2018 Aug; 27(8):926-930. PubMed ID: 29923251
[TBL] [Abstract][Full Text] [Related]
12. A systematic assessment of the association between frequently prescribed medicines and the risk of common cancers: a series of nested case-control studies.
McDowell RD; Hughes C; Murchie P; Cardwell C
BMC Med; 2021 Jan; 19(1):22. PubMed ID: 33494748
[TBL] [Abstract][Full Text] [Related]
13. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
14. Drug Utilisation Patterns of Alternatives to Ranitidine-Containing Medicines in Patients Treated with Ranitidine: A Network Analysis of Data from Six European National Databases.
Arinze JT; de Ridder MAJ; Vojinovic D; van Ballegooijen H; Markov E; Duarte-Salles T; Rijnbeek P; Verhamme KMC
Drug Saf; 2023 Dec; 46(12):1353-1362. PubMed ID: 37907775
[TBL] [Abstract][Full Text] [Related]
15. Ranitidine-induced anaphylaxis: clinical features, cross-reactivity, and skin testing.
Park KH; Pai J; Song DG; Sim DW; Park HJ; Lee JH; Jeong KY; Pan CH; Shin I; Park JW
Clin Exp Allergy; 2016 Apr; 46(4):631-9. PubMed ID: 26764898
[TBL] [Abstract][Full Text] [Related]
16. Prescription changes in patients with gastrointestinal disorders after withdrawal of ranitidine: a nationwide population-based cohort study.
Ku M; Je NK
Curr Med Res Opin; 2023 Feb; 39(2):197-203. PubMed ID: 36519289
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study.
Bradley MC; Murray LJ; Cantwell MM; Hughes CM
Br J Cancer; 2012 Jan; 106(1):233-9. PubMed ID: 22108522
[TBL] [Abstract][Full Text] [Related]
18. Ranitidine Use and Cancer Risk: Results From UK Biobank.
Kantor ED; O'Connell K; Du M; Mendelsohn RB; Liang PS; Braunstein LZ
Gastroenterology; 2021 Apr; 160(5):1856-1859.e5. PubMed ID: 33385434
[No Abstract] [Full Text] [Related]
19. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
20. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children.
Canani RB; Cirillo P; Roggero P; Romano C; Malamisura B; Terrin G; Passariello A; Manguso F; Morelli L; Guarino A;
Pediatrics; 2006 May; 117(5):e817-20. PubMed ID: 16651285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
